My ePortfolio Register   

New key regulator of acquisition of immune tolerance to tumour cells in cancer patients

Researchers of the Chromatin and Disease Group from the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona have identified a distinctive epigenetic event in immune cells that differentiate in the tumoural microenvironment and make them tolerant to cancer cells.

In the past few years, there has been increasing evidence that inflammatory factors released in the tumour microenvironment are able to redirect the differentiation of immune-promoting dendritic cells to myeloid-derived suppressor cells, which decrease the ability of the cancer patient immune system to fight against the cancer cells.

A number of studies have identified factors, such as as prostaglandin E2, that have the capacity to subvert the immunity of the cancer patients.

In this study, published today in the journal Cell Reports, and led by Dr. Esteban Ballestar (IDIBELL), the comparison of the epigenetic profiles between dendritic cells and myeloid-derived suppressor cells has allowed them to identify the existence of specific epigenetic alterations that associated with the development of myeloid-derived suppressor cells as a result of exposure to prostaglandin E2.

The team has been able to prove that such epigenetic alterations are associated with the increased levels of an enzyme, namely DNA methyltransferase 3A (DNMT3A), which is responsible for the acquisition of the suppressive properties of these cells that develop in the tumoural microenvironment.

Inhibition of DNMT3A resulted in erasing the suppressive properties of these cells.

One of the most relevant findings of this study is that the observed epigenetic features of these cells are also present in myeloid-derived suppressor cells isolated from patients with ovarian carcinoma.

Given the interest in developing drugs against DNA methyltransferases, the results by this team open up potential therapeutic opportunities for further exploration.




Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence